Compare CABR & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABR | CALC |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 9.7M |
| IPO Year | N/A | 2020 |
| Metric | CABR | CALC |
|---|---|---|
| Price | $1.26 | $0.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 62.0K | ★ 1.0M |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.31 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $0.46 |
| 52 Week High | $1.73 | $7.20 |
| Indicator | CABR | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 41.23 |
| Support Level | $0.80 | $0.52 |
| Resistance Level | $1.36 | $0.76 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 27.12 | 19.28 |
Caring Brands Inc is a wellness consumer products company. It offers several over-the-counter (OTC) and cosmetic consumer products. Its product pipeline includes a diverse products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products, catering to diverse health and wellness needs. It operates in a single segment.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.